Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Revenue of Arrowhead Pharmaceuticals, Inc. (ARWR)
Revenue in 2024 (TTM): $3.55 M
According to Arrowhead Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $3.55 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Arrowhead Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2024 | $3.55 M | $3.55 M | $-561,513,000 | $-602,260,000 | $-599,493,000 |
| 2023 | $240.74 M | $240.74 M | $-175,672,000 | $-206,491,000 | $-205,275,000 |
| 2022 | $243.23 M | $232.81 M | $-162,288,000 | $-172,709,000 | $-176,494,000 |
| 2021 | $138.29 M | $138.29 M | $-132,580,000 | $-140,846,000 | $-140,848,000 |
| 2020 | $87.99 M | $87.99 M | $-87,217,000 | $-84,550,826 | $-84,553,226 |
| 2019 | $168.8 M | $168.8 M | $65.63 M | $68.15 M | $67.97 M |
| 2018 | $16.14 M | $16.14 M | $-51,236,960 | $-54,448,078 | $-54,450,478 |
| 2017 | $31.41 M | $31.41 M | $-29,687,456 | $-34,377,895 | $-34,380,295 |
| 2016 | $158.33 K | $158.33 K | $-78,460,559 | $-81,720,602 | $-81,723,002 |
| 2015 | $382 K | $382 K | $-89,602,274 | $-91,938,482 | $-91,940,882 |
| 2014 | $175 K | $175 K | $-47,382,586 | $-58,720,112 | $-58,630,190 |
| 2013 | $290.27 K | $290.27 K | $-20,108,165 | $-31,703,079 | $-31,143,289 |
| 2012 | $146.88 K | $146.88 K | $-19,340,236 | $-22,110,643 | $-21,125,928 |
| 2011 | $296.14 K | $296.14 K | $-8,517,031 | $-8,785,008 | $-3,128,885 |
| 2010 | $620.1 K | $620.1 K | $-6,681,665 | $-7,336,355 | $-5,774,048 |
| 2009 | $3.77 M | $3.77 M | $-18,162,956 | $-19,157,561 | $-19,308,392 |
| 2008 | $1.3 M | $1.3 M | $-33,247,586 | $-35,117,310 | $-27,089,030 |
| 2007 | $1.21 M | $483.93 K | $-35,680,281 | $-37,948,843 | $-29,931,118 |
| 2006 | $595.46 K | $595.46 K | $-19,426,839 | $-21,924,006 | $-18,997,209 |
| 2005 | $590.68 K | $590.68 K | $-8,948,842 | $-6,987,885 | $-6,624,824 |
| 2004 | $196.31 K | $196.31 K | $-2,673,122 | $-2,496,142 | $-2,496,942 |
| 2003 | $ | $ | $-94,348 | $-94,438 | $-95,238 |
| 2002 | $2.27 K | $2.18 K | $-1,407,136 | $-246,207 | $-246,207 |
| 2001 | $9.31 K | $3.02 K | $-102,739 | $-185,821 | $-185,821 |
| 2000 | $24.88 K | $22.78 K | $-101,613 | $-137,553 | $-137,553 |
| 1999 | $37 K | $34.15 K | $-48,096 | $-368,459 | $593 K |
| 1998 | $60.38 K | $26.59 K | $-15,111 | $-10,535 | $-51,620 |
| 1997 | $76.59 K | $39.62 K | $-54,833 | $-854,535 | $-854,535 |